Resmiterom Efficacy & Safety in Patients With MASH
Recruiting
Phase 4
Interventional Study
MASH - Metabolic Dysfunction-Associated Steatohepatitis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 165 (estimated)
- Sponsor
- Nabiqasim Industries (Pvt) Ltd · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* • At least one metabolic comorbidity (e.g., T2DM, obesity, dyslipidemia and hypertension)
* Clinical diagnosis of MASH using:
* LSM ≥ 8.5kpa And/or
* FAST score ≥0.67 And/or
* FibroScan CAP ≥ 275 dB/m And/or
* FIB-4 \> 1.3
Exclusion Criteria:
* • History …
Contacts